Novartis AG (NVS): Price and Financial Metrics

Novartis AG (NVS)

Today's Latest Price: $87.57 USD

0.28 (-0.32%)

Updated Jul 2 7:00pm

Add NVS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVS Stock Summary

  • Novartis Ag's market capitalization of $197,825,841,342 is ahead of 99.42% of US-listed equities.
  • In terms of volatility of its share price, NVS is more volatile than only 1.36% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NVS comes in at 8.56% -- higher than that of 80.07% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novartis Ag are MRK, PFE, CSCO, NFLX, and DIS.
  • NVS's SEC filings can be seen here. And to visit Novartis Ag's official web site, go to
NVS Daily Price Range
NVS 52-Week Price Range

NVS Stock Price Chart Technical Analysis Charts

NVS Price/Volume Stats

Current price $87.57 52-week high $99.84
Prev. close $87.85 52-week low $69.18
Day low $87.39 Volume 1,101,452
Day high $88.07 Avg. volume 2,364,362
50-day MA $86.52 Dividend yield 2.3%
200-day MA $88.34 Market Cap 200.42B

Novartis AG (NVS) Company Bio

Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.

NVS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novartis Ag. To summarize, we found that Novartis Ag ranked in the 38th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for NVS, they are:

  • The compound growth rate in the free cash flow of Novartis Ag over the past 5.01 years is 0.03%; that's higher than only 24.62% of free cash flow generating stocks in the Healthcare sector.
  • NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 35.34% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVS, try HRC, MDT, BDX, USPH, and LCI.

NVS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

NVS Latest Social Stream

Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about Novartis Ag that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Novartis finalizes $678M settlement to resolve kickback claims

Ending almost a decade of litigation, Novartis (NVS) has agreed to pay $678M to resolve a whistleblower case accusing the drugmaker of paying kickbacks to thousands of doctors who prescribed its medicines.As part of the settlement, Novartis will change how the company markets its drugs to doctors as part of...

Seeking Alpha | July 2, 2020

Novartis finalizes $678M settlement to resolve kickback claims (NYSE:NVS)

Ending almost a decade of litigation, Novartis (NYSE:NVS) has agreed to pay $678M to resolve a whistleblower case accusing the drugmaker of paying kickback

Seeking Alpha | July 2, 2020

European Antibiotics Market Assessment and Forecast to 2027 with Profiles of GlaxoSmithKline, Sanofi, Novartis, Bayer and Pfizer -

DUBLIN--(BUSINESS WIRE)--The "Europe Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country" report has been added to's offering. The European antibiotics market is expected to reach US$ 15,569.8 million by 2027 from US$ 12,457.7 million in 2019. The market is estimated to grow with a CAGR of 3.1% from 2020 to 2027. The antibiotics market is growing primarily due to prevalence of infectious diseases and inc

Business Wire | July 2, 2020

Novartis agrees to US$642 mil settlement over kickbacks to doctors

The pharmaceutical giant spent hundreds of millions of dollars to get doctors to prescribe its drugs.

Free Malaysia Today | July 2, 2020

Novartis Settles $678M Fraud Lawsuit Alleging It Bribed Doctors At Company Speaker Events

Novartis AG (NYSE: NVS ) has reached a $678 million settlement in a civil fraud lawsuit that alleged the company bribed doctors at speaker events it organized. What Happened The agreement was made with the U.S. Attorney’s Office for the Southern District of New York, the New York State Attorney General, and the whistleblower Oswald Bilotta. The Government complaint had alleged that between 2002 and 2011, Novartis hosted “tens of thousands” of speaker programs but used these opportunities to bribe doctors. The United States Department of Justice alleged that Novartis violated that federal False Claims Act and Anti-Kickback Statute by providing doctors with cash payments and other inducements, … Full story available on

Benzinga | July 2, 2020

Read More 'NVS' Stories Here

NVS Price Returns

1-mo 1.96%
3-mo 2.15%
6-mo -5.12%
1-year -0.88%
3-year 31.53%
5-year 15.73%
YTD -5.33%
2019 28.03%
2018 5.95%
2017 18.80%
2016 -12.56%
2015 -4.52%

NVS Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8544 seconds.